Induction of apoptosis in cancer: new therapeutic opportunities

Reference

• Kerr JF, Wyllie AH, Currie Alt Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–57.
   PubMed Web of Science ®Google Scholar
• Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990; 68: 1071–4.
   PubMed Web of Science ®Google Scholar
• Ellis RE, Yuan J, Horvitz HR. Mechanisms and functions of cell death. Annu Rev Cell Biol 1991; 7: 663–98.
   PubMed Web of Science ®Google Scholar
• Jacobson MD, Weil M, Raff MC. programmed cell death in animal development. Cell 1997; 88: 347–54.
   PubMed Web of Science ®Google Scholar
• Kuida K, Zheng TS, Na S, Kuan C-Y, Yang D, Karasuya- ma H, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996; 384: 368–72.
   PubMed Web of Science ®Google Scholar
• Kuida K, Haydar TF, Kuan C-Y, Gu Y, Taya C, Kara- suyama H, et al. Reduced apoptosis and cytochrome c- mediated caspase activation in mice lacking caspase 9. Cell 1998; 94: 325–37.
   PubMed Web of Science ®Google Scholar
• Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998; 94: 339–52.
   PubMed Web of Science ®Google Scholar
• Varfolomeev EE, Schuchmann M, Luria V, Chiannilkul- chai N, Bechmann JS, Mett IL, et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apot, and DR3 and is lethal prenatally. Immunity 1998; 9: 267–76.
   PubMed Web of Science ®Google Scholar
• Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–62.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097–9.
   PubMed Web of Science ®Google Scholar
• Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899–906.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bc1-2 and a hybrid bc1-2/immunoglo-bulin transcript resulting from the t(14;18) translocation. Cell 1986; 47: 19–28.
   PubMed Web of Science ®Google Scholar
• Vaux DL, Cory S, Adams JM. Bc1-2 gene promotes a haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–2.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, et al. bc1-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lympho- proliferation. Cell 1989; 57: 79–88.
   PubMed Web of Science ®Google Scholar
• McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254–6.
   PubMed Web of Science ®Google Scholar
• Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391–9.
   Google Scholar
• Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870–8.
   PubMed Web of Science ®Google Scholar
• Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 1990; 2: 275–80.
   PubMed Web of Science ®Google Scholar
• Hidcman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121–39.
   PubMedGoogle Scholar
• Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941–53.
   Google Scholar
• Cryns V, Yuan J. Proteases to die for. Genes Dev 1998; 12: 1551–70.
   PubMed Web of Science ®Google Scholar
• Aravind L, Dixit VM, Koonin EV. Apoptotic molecular machinery: vastly increased complexity in vertebrates re-vealed by genome comparisons. Science 2001; 291: 1279–84.
   PubMed Web of Science ®Google Scholar
• Hengartner M. The biochemistry of apoptosis. Nature 2000; 407: 770–6.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305–8.
   PubMed Web of Science ®Google Scholar
• Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29–55.
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing sig-naling complex (DISC) with the receptor. EMBO J 1995; 14: 5579–88.
   PubMed Web of Science ®Google Scholar
• Yang X, Chang HY, Baltimore D. Autoproteolytic activa- tion of pro-caspases by oligomerization. Mol Cell 1998; 1: 319–25.
   PubMed Web of Science ®Google Scholar
• Muzio M, Stockwell BR, Stennicke HR, Salvesen GS, Dixit VM. An induced proximity model for caspase-8 activation. J Biol Chem 1998; 273: 2926–30.
   PubMed Web of Science ®Google Scholar
• Fesik SW. Insights into programmed cell death through structural biology. Cell 2000; 103: 273–82.
   PubMed Web of Science ®Google Scholar
• Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309–12.
   PubMed Web of Science ®Google Scholar
• Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922–33.
   PubMed Web of Science ®Google Scholar
• Wei MC, Zong W-X, Cheng EH-Y, Lindsten T, Panoutsa- kopoulou V, Ross AJ, et at. Proapoptotic Bax and Bak: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727–30.
   PubMed Web of Science ®Google Scholar
• Liu XS, Kim CN, Yang J, Jemmerson R, Wang XD. Induction of apoptotic program in cell-free extracts - requirement for dATP and cytochrome c. Cell 1996; 86: 147–57.
   PubMed Web of Science ®Google Scholar
• Susin SA, Zamzami N, Castedo M, Hirsch T, Marchetti P, Macho A, et al. Bc1-2 inhibits the mitochondrial release of an apoptogenic protease. J Exp Med 1996; 184: 1331–41.
   PubMed Web of Science ®Google Scholar
• Du C, Fang M, Li Y, Li L, Wang X. smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33–42.
   PubMed Web of Science ®Google Scholar
• Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et at. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antag- onizing TAP proteins. Cell 2000; 102: 43–53.
   PubMed Web of Science ®Google Scholar
• Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999; 274: 17941–5.
   PubMed Web of Science ®Google Scholar
• Zou H, Li Y, Liu X, Wang X. An Apaf-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549–56.
   PubMed Web of Science ®Google Scholar
• Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, partici-pates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405–13.
   PubMed Web of Science ®Google Scholar
• Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479–89.
   Google Scholar
• Stinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-l-mediated oligomerization. Mol Cell 1998; 1: 949–57.
   PubMedGoogle Scholar
• Li H, Zhu H, Xu C-J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491–501.
   PubMed Web of Science ®Google Scholar
• Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bc12 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481–90.
   PubMed Web of Science ®Google Scholar
• Eskes R, Desagher S, Antonsson B, Martinou J. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial members. Mol Cell Biol 2000; 20: 929–35.
   PubMed Web of Science ®Google Scholar
• Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14: 2060–71.
   PubMed Web of Science ®Google Scholar
• Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993; 67: 2168–74.
   PubMed Web of Science ®Google Scholar
• Birnbaum MJ, Clem RJ, Miller LK. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypep-tide with Cys/His sequence motifs. J V irol 1994; 68: 2521–8.
   Google Scholar
• Verhagen AM, Coulson EJ, Vaux DI- Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001; 2: 1–10.
   Google Scholar
• Sun C, Cai M, Meadows RP, Xu N, Gunasekera AH, Herrmann J, et al. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem 2000; 275: 33777–81.
   PubMedGoogle Scholar
• Stinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apopto-sis. Nature 2001; 410: 112–6.
   PubMedGoogle Scholar
• Riedl SJ, Renatus M, Schwarzenbacher R, Zhou Q, Sun C, Fesik SW, et al. Structural basis for the inhibition of caspase- 3 by XIAP. Cell 2001; 104: 791–800.
   PubMed Web of Science ®Google Scholar
• alai J, Shiozaki E, Srinivasula SM, Wu Q, Datta P, Alnemri ES, et at. Structural basis of caspase-7 inhibition by XIAP. Cell 2001; 104: 769–80.
   PubMedGoogle Scholar
• Huang Y, Park YC, Rich RL, Segal D, Myszka DG, Wu H. Structural basis of caspase inhibition by XIAP: differential roles of the linker versus the BIR domain. Cell 2001; 104:781–90.
   PubMed Web of Science ®Google Scholar
• Ashhab Y, Alian A, Polliack A, Panet A, Yehuda DB. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001; 495: 56–60.
   PubMed Web of Science ®Google Scholar
• Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238–46.
   PubMed Web of Science ®Google Scholar
• Vucic D, Stennicke FIR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10: 1359–66.
   PubMed Web of Science ®Google Scholar
• Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002; 9: 459–70.
   PubMed Web of Science ®Google Scholar
• Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzou-nova M, Hernandez JM, Hossfeld DK, et al. The apop- tosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601–9.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida c, Alfieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917–21.
   PubMed Web of Science ®Google Scholar
• Alfieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542–7.
   PubMedGoogle Scholar
• Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954–61.
   PubMed Web of Science ®Google Scholar
• Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by com-parative genomic hybridization. Am J Pathol1997; 150: 81–9.
   Google Scholar
• Islam A, Kageyama H, Takada N, Kawamato T, Takayasu H, Isogai E, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Onco-gene 2000; 19: 617–23.
   Google Scholar
• Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M, et al. The inhibitor of apoptosis protein Survivin is associated with high-risk behavior of neuroblas-toma. J Pediatr Surg 2001; 36: 1785–91.
   PubMed Web of Science ®Google Scholar
• Tajiri T, Tanaka S, Shono K, Kinoshita Y, Fujii Y, Suita S, et al. Quick quantitative analysis of gene dosages associated with prognosis in neuroblastoma. Cancer Lett 2001; 166: 89–94.
   PubMedGoogle Scholar
• Adams JM, Cory S. The Bc1-2 protein family: arbiters of cell survival. Science 1998; 281: 1322–6.
   PubMed Web of Science ®Google Scholar
• Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899–911.
   PubMed Web of Science ®Google Scholar
• Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, et al. The combined functions of proapoptotic Bc1-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389–99.
   PubMed Web of Science ®Google Scholar
• Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain- only molecules preventing BAX- and BAK-mediated mito-chondrial apoptosis. Mol Cell 2001; 8: 705–11.
   PubMed Web of Science ®Google Scholar
• Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967–9.
   PubMed Web of Science ®Google Scholar
• Meijerink JP, Mensink EJ, Wang K, Sedlak TV/, Sloetjes AW, de Witte T, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998; 91: 2991–7.
   PubMed Web of Science ®Google Scholar
• Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S, et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000; 60: 4328–30.
   PubMed Web of Science ®Google Scholar
• TschopP J, limier M, Thome M. Inhibition of Fas death signals by FLIPs. Curr Opin Immunol 1998; 10: 552–8.
   PubMed Web of Science ®Google Scholar
• Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517–21.
   Google Scholar
• Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, Banks S, et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc Nat! Acad Sci USA 1997; 94: 1172–6.
   PubMed Web of Science ®Google Scholar
• Hu S, Vincenz C, Buller M, Dixit VM. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-l-induced apoptosis. J Biol Chem 1997; 272: 9621–4.
   PubMed Web of Science ®Google Scholar
• Goltsev YV, Kovalenko AV, Arnold E, Varfolomeev EE, Brodianskii VM, Wallach D. CASH, a novel caspase homologue with death effector domains. J Biol Chem 1997; 272: 19641–4.
   PubMed Web of Science ®Google Scholar
• Han DKM, Chaudhary PM, Wright ME, Friedman C, Trask BJ, Riedel RT, et al. MRIT, a novel death-effector domain-containing protein, interacts with caspases and BcLX1. and initiates cell death. Proc Nat! Acad Sci USA 1997; 94: 11333–8.
   PubMed Web of Science ®Google Scholar
• Hu S, Vincenz C, Ni J, Gentz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD- 95-induced apoptosis. J Biol Chem 1997; 272: 17255–7.
   PubMed Web of Science ®Google Scholar
• Inohara N, Koseki T, Hu Y, Chen S, Nunez G. CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. Proc Nat! Acad Sci USA 1997; 94: 10717–22.
   PubMedGoogle Scholar
• Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190–5.
   PubMed Web of Science ®Google Scholar
• Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, et al. Cell death attenuation by `Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 1998; 5: 271–88.
   PubMed Web of Science ®Google Scholar
• Shu HB, Halpin DR, Goeddel DV. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 1997; 6: 751–63.
   Google Scholar
• Srinivasula SM, Ahmad M, Ottilie S, Bullrich F, Banks S, Wang Y, et al. FLAME-1, a novel FADD-like anti-apoptotic molecule that regulates Fas/TNFR1-induced apoptosis. J Biol Chem 1997; 272: 18542–5.
   PubMed Web of Science ®Google Scholar
• Yeh W-C, hie A, Elia A, Ng M, Shu H-B, Wakeham A, et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000; 12: 633–42.
   PubMed Web of Science ®Google Scholar
• Yeh W-C, de la Pompa JL, McCurrach ME, Shu H-B, Elia AJ, Shahinian A, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998; 279: 1954–8.
   PubMed Web of Science ®Google Scholar
• Ryu BK, Lee MG, Chi SG, Kim YW, Park JR. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 2001; 194: 15–9.
   PubMed Web of Science ®Google Scholar
• Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, Saurat JH, et al. Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol 2001; 117: 360–4.
   PubMed Web of Science ®Google Scholar
• Djerbi M, Screpanti V, Catrina Al, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999; 190: 1025–31.
   PubMed Web of Science ®Google Scholar
• Meclema JP, de Jong J, van Hall T, Melief CJM, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190: 1033–8.
   PubMedGoogle Scholar
• Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905–27.
   PubMed Web of Science ®Google Scholar
• Talapatra S, Thompson CB. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 2001; 298: 873–8.
   PubMedGoogle Scholar
• Dana SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell- intrinsic death machinery. Cell 1997; 91: 231–41.
   Google Scholar
• del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687–9.
   PubMed Web of Science ®Google Scholar
• Cardone MH, Roy N, Stennicke FIR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318–21.
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonn A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857–68.
   PubMed Web of Science ®Google Scholar
• Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF- KB by the Akt/PKB kinase. Curr Biol 1999; 9: 601–4.
   Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-KB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002; 2: 301–10.
   PubMed Web of Science ®Google Scholar
• Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983–5.
   PubMed Web of Science ®Google Scholar
• Simpson L, Parsons It PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264: 29–41.
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, etal. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–7.
   PubMed Web of Science ®Google Scholar
• Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356–62.
   Google Scholar
• Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124–9.
   Google Scholar
• Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348–55.
   PubMed Web of Science ®Google Scholar
• Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor re in mice. Curr Biol 1998; 8: 1169–78.
   PubMed Web of Science ®Google Scholar
• Podsypamna K, E lenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten/Mmacl in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563–8.
   PubMedGoogle Scholar
• Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, et al. P-TEN, the tumor suppressor from human chromo-some 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 1997; 94: 9052–7.
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon, TF. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998; 273: 13375–8.
   PubMed Web of Science ®Google Scholar
• Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998; 95: 13513–8.
   PubMed Web of Science ®Google Scholar
• Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998; 8: 1195–8.
   PubMed Web of Science ®Google Scholar
• Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt- dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29–39.
   PubMed Web of Science ®Google Scholar
• Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase func-tions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Nat! Acad Sci USA 1998; 95: 15587–91.
   PubMed Web of Science ®Google Scholar
• Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, et aL Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 1998; 58: 5285–90.
   PubMed Web of Science ®Google Scholar
• Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonics N, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998; 58: 5667–72.
   PubMed Web of Science ®Google Scholar
• Vousden K. p53: death star. Cell 2000; 103: 691–4.
   PubMed Web of Science ®Google Scholar
• Vugelstein B, Lane D, Levine A. Surfing the p53 network. Nature 2000; 408: 307–10.
   PubMedGoogle Scholar
• Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296–9.
   PubMed Web of Science ®Google Scholar
• Kubbutat MH, Jones SN, Vousden KFL Regulation of p53 stability by Mdm2. Nature 1997; 387: 299–303.
   PubMed Web of Science ®Google Scholar
• Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27: 247–54.
   PubMed Web of Science ®Google Scholar
• Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland it, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immor-talization. Genes Dev 1998; 12: 2422–33.
   Google Scholar
• de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, et ..4• FAA signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998; 12: 2434–42.
   PubMed Web of Science ®Google Scholar
• Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993–1000.
   PubMed Web of Science ®Google Scholar
• Stott FJ, Bates S, James MC, McConnel BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feed-back loop with p53 and MDM2. EMBO J 1998; 17: 5001–14.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725–34.
   PubMed Web of Science ®Google Scholar
• Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, et al. The Ink4a tumor suppressor gene product, pl9Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713–23.
   PubMed Web of Science ®Google Scholar
• Kamijo T, Weber JD, Zambetti F, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95: 8292–7.
   PubMed Web of Science ®Google Scholar
• El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25.
   PubMed Web of Science ®Google Scholar
• Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–16.
   PubMed Web of Science ®Google Scholar
• Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993; 366: 707–10.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–4.
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821–8.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bc1-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–805.
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BF13-only member of the bc1-2 family and candidate mediator of p53-induced apoptosis. Science 2000; 288: 1053–8.
   PubMed Web of Science ®Google Scholar
• Oda K, Aralcawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, et al. p53A1P1, a potential mediator of p53- dependent apoptosis, and its regulation by Ser-46-phos-phorylated p53. Cell 2000; 102: 849–62.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang L, Hwang P, Kinzler K, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673–82.
   PubMed Web of Science ®Google Scholar
• Nakano K, Vousden K. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683–94.
   PubMed Web of Science ®Google Scholar
• Moroni MC, Hichman ES, Denchi EL, Caprara G, Golli E, Cecconi F, et al. Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biol 2001; 3: 552–8.
   PubMed Web of Science ®Google Scholar
• Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15: 3032–40.
   Google Scholar
• Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403–13.
   Google Scholar
• Tamura T, Aoyama N, Saya H, Haga H, Futami S, Miyamoto M, et al. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 1995; 11: 1939–46.
   Google Scholar
• Reinke V, Lozano G. The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 1997; 15: 1527–34.
   Google Scholar
• Wu G, Burns T, McDonald E, Ill, Jiang W, Meng R, Krantz I, et al. KILLER/DRS is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141–3.
   Google Scholar
• Lin Y, Ma W, Benchimol S. Pidd, a new death-domain- containing protein, is induced by p53 and promotes apopto- sis. Nat Genet 2000; 26: 124–7.
   Google Scholar
• Caelles C, Hehnberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220–3.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Kokontis JM, Hay N. myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p2lwafUcipl. Genes Dev 1994; 8: 2817–30.
   PubMed Web of Science ®Google Scholar
• Rowan S, Ludwig RI, Haupt Y, Bates S, Lu X, Oren M, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15: 827–38.
   PubMed Web of Science ®Google Scholar
• Aurelio ON, Cajot J-F, Hua ML-H, Khwaja Z, Stanbridge Germ-line-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions. Cancer Res 1998; 58: 2190–5.
   PubMedGoogle Scholar
• Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M. Induction of apoptosis in HeLa cells by trans-activation- deficient p53. Genes Dev 1995; 9: 2170–83.
   Google Scholar
• Chen X, Ko L, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10: 2438–51.
   PubMed Web of Science ®Google Scholar
• Ding H-F, Lin Y-L, McGill G, Juo P, Zhu H, Blenis J, et al. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem 2000; 275: 38905–11.
   PubMedGoogle Scholar
• Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, et al. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat Genet 2000; 26: 37–43.
   PubMed Web of Science ®Google Scholar
• Fisher DE. Apoptosis in cancer therapy: crossing the thresh- old. Cell 1994; 78: 539–42.
   PubMedGoogle Scholar
• Lowe SW, Ruley HE, Jacks T, Housman DE. p53_ dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957–67.
   PubMed Web of Science ®Google Scholar
• Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996; 24: 141–6.
   PubMed Web of Science ®Google Scholar
• Attardi LD, Jacks T. The role of P53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999; 55: 48–63.
   Google Scholar
• Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1: 289–98.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.
   PubMed Web of Science ®Google Scholar
• Dang CV. c-myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1–11.
   PubMed Web of Science ®Google Scholar
• Eisenman RN. Deconstructing myc. Genes Dev 2001; 15: 2023–30.
   PubMed Web of Science ®Google Scholar
• Sheiness D, Fanshier L, Bishop JM. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol 1978; 28: 600–10.
   PubMed Web of Science ®Google Scholar
• Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induced lymphoid malignancy in transgenic mice. Nature 1985; 318: 533–8.
   PubMed Web of Science ®Google Scholar
• Schoenenberger CA, Andres AC, Groner B, van der Valk M, LeMeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. EMBO J 1988; 7: 169–75.
   PubMed Web of Science ®Google Scholar
• Skoda RC, Tsai SF, Orkin SH, Leder P. Expression of c-MYC under the control of GATA-1 regulatory sequences causes erythroleukemia in transgenic mice. J Exp Med 1995; 181: 1603–13.
   PubMedGoogle Scholar
• Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4: 199–207.
   PubMed Web of Science ®Google Scholar
• Marcu KB, Bossone SA, Patel AJ. myc function and regulation. Annu Rev Biochem 1992; 61: 809–60.
   PubMed Web of Science ®Google Scholar
• Armelin HA, Armelin MC, Kelly K, Stewart T, Leder P, Cochran BH, et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature 1984; 310: 655–60.
   PubMed Web of Science ®Google Scholar
• Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the alpha-prothymosin gene. EMBO J 1991; 10: 133–41.
   PubMed Web of Science ®Google Scholar
• Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915–22.
   PubMed Web of Science ®Google Scholar
• Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119–28.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Claassen G, Shi J, Adachi S, Sedivy J, Hann SR. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev 1998; 12: 3803–8.
   PubMedGoogle Scholar
• Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284: 156–9.
   PubMed Web of Science ®Google Scholar
• Green DR, Evan G. A matter of life and death. Cancer Cell 2002; 1: 19–30.
   PubMed Web of Science ®Google Scholar
• Fanidi A, Harrington E, Evan G. Cooperative interaction between c-myc and bc1-2 proto-oncogenes. Nature 1992; 359: 554–6.
   PubMed Web of Science ®Google Scholar
• Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bc1-2. Nature 1992; 359: 552–4.
   PubMed Web of Science ®Google Scholar
• Juin P, Hueber A-O, Littlewood T, Evan G. c-Myc-induced sensitization to apotosis is mediated through cytochrome c release. Genes Dev 1999; 13: 1367–81.
   PubMed Web of Science ®Google Scholar
• Hueber A-O, Zomig M, Lyon D, Suda T, Nagata S, Evan G. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 1997; 278: 1305–9.
   PubMed Web of Science ®Google Scholar
• Klefstrom J, Aright E, Litdewood T, Jaattel a M, Saksela E, Evan GI, et al. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-KB activation. EMBO J 1997; 16: 7382–92.
   PubMedGoogle Scholar
• Henneking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994; 265: 2091–3.
   PubMed Web of Science ®Google Scholar
• Schmitt CA, McCurrach ME, de Stanchina E, Wallace- Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13: 2670–7.
   PubMed Web of Science ®Google Scholar
• Lindstrom MS, Klangby U, Wiman KG. p14ARF homo- zygous deletion or MDM2 overexpression in Burkitt lym-phoma lines carrying wild type p53. Oncogene 2001; 20: 2171–7.
   PubMed Web of Science ®Google Scholar
• Hiebert SW, Padcham G, Strom DK, Haffner R, Oren M, Zambetti G, et al. E2f-1/dp-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 1995; 15: 6864–74.
   Google Scholar
• Kowalik TF, DeGregori J, Leone G, Jakoi L, Nevins JR. E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 1998; 9: 113–8.
   PubMedGoogle Scholar
• Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124–5.
   PubMed Web of Science ®Google Scholar
• Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002; 277: 11617–20.
   PubMedGoogle Scholar
• Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell 2001; 8: 105–13.
   PubMedGoogle Scholar
• Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC, et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res 2000; 60: 6318–25.
   PubMed Web of Science ®Google Scholar
• Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245–62.
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30.
   PubMed Web of Science ®Google Scholar
• DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 1997; 94: 7245–50.
   PubMed Web of Science ®Google Scholar
• Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Hemp K, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992; 359: 288–94.
   PubMed Web of Science ®Google Scholar
• Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 1992; 359: 295–300.
   PubMed Web of Science ®Google Scholar
• Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, et al. Requirement for a functional Rb-1 gene in murine development. Nature 1992; 359: 328–30.
   PubMed Web of Science ®Google Scholar
• Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb- deficient mouse embryos. Mol Cell 1998; 2: 293–304.
   PubMed Web of Science ®Google Scholar
• Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, et al. E2f-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549–61.
   PubMed Web of Science ®Google Scholar
• Qin XQ, Livingston DM, Kaelin WJ, Adams PD. Deregu- lated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 10918–22.
   PubMed Web of Science ®Google Scholar
• Shan B, Lee W-FL Dereguolated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994; 14: 8166–73.
   PubMedGoogle Scholar
• Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol 1995; 69: 2491–500.
   Google Scholar
• Wu X, Levine AJ. p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 1994; 91: 3602–6.
   PubMed Web of Science ®Google Scholar
• Morgenbesser SD, Williams BO, Jacks T, DePinho RA. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 1994; 371: 72–4.
   PubMed Web of Science ®Google Scholar
• Macleod KF, Hu Y, Jacks T. Loss of Rb activates both p53- dependent and independent cell death pathways in the developing mouse nervous system. EMBO J 1996; 15: 6178–88.
   Google Scholar
• Jost CA, Mann MC, Kaelin WG, Jr. p73 is a human p53- related protein that can induce apoptosis. Nature 1997; 389: 191–4.
   PubMed Web of Science ®Google Scholar
• Irwin M, Mann MC, Phillips AC, Seelan RS, Smith DI, Liu W, et al. Role for the p53 homologue p73 in E2F-1- induced apoptosis. Nature 2000; 407: 645–8.
   PubMed Web of Science ®Google Scholar
• Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 1997; 11: 1840–52.
   Google Scholar
• Phillips AC, Bates S, Ryan KM, Helin K, Vousden KH. Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 1997; 11: 1853–63.
   Google Scholar
• Phillips AC, Ernst MK, Bates S, Rice NR, Vousden KH. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 1999; 4: 771–81.
   PubMedGoogle Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682–9.
   PubMed Web of Science ®Google Scholar
• Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991; 349: 117–27.
   PubMed Web of Science ®Google Scholar
• Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998; 8: 49–54.
   PubMedGoogle Scholar
• Frame S, Bafinain A. Integration of positive and negative growth signals during ras pathway activation in vivo. Curr Opin Genet Dev 2000; 10: 106–13.
   PubMedGoogle Scholar
• Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983; 304: 602–6.
   PubMed Web of Science ®Google Scholar
• Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperat-ing oncogenes. Nature 1983; 304: 596–602.
   PubMed Web of Science ®Google Scholar
• Debbas M, White E. Wild-type p53 mediates apoptosis by MA, which is inhibited by MB. Genes Dev 1993; 7: 546–54.
   PubMed Web of Science ®Google Scholar
• Rao L, Debbas P, Sabbatini P, Hockenberry D, Korsmeyer S, White E. The adenovirus MA proteins induces apoptosis which is inhibited by the MB 19K and Bc1-2 proteins. Proc Natl Acad Sci USA 1992; 89: 7742–6.
   PubMed Web of Science ®Google Scholar
• Tsuneoka M, Mekada E. Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras. Oncogene 2000; 19: 115–23.
   PubMed Web of Science ®Google Scholar
• Kauffinann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc- induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997; 385: 544–8.
   PubMedGoogle Scholar
• Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI, et al. Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 1997; 57: 362–5.
   Google Scholar
• Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000; 60: 6597–600.
   PubMed Web of Science ®Google Scholar
• Wolfinan JC, Wolfinan A. Endogenous c-N-Ras provides a steady-state anti-apoptotic signal. J Biol Chem 2000; 275: 19315–23.
   PubMedGoogle Scholar
• Bergmann A, Agapite J, McCall K, Steller H. The Drosophila gene hid is a direct molecular target of Ras-dependent survival signaling. Cell 1998; 95: 331–41.
   PubMed Web of Science ®Google Scholar
• Kurada P, White K. Ras promotes cell survival in Drosophila by downregulating hid expression. Cell 1998; 95: 319–29.
   PubMed Web of Science ®Google Scholar
• Gomez J, Martinez C, Fernandez B, Garcia A, Rebollo A. Ras activation leads to cell proliferation or apoptotic cell death upon interleukin-2 stimulation or lymphokine depriva-tion, respectively. Eur J Immunol 1997; 27: 1610–8.
   PubMedGoogle Scholar
• Henkemeyer M, Rossi DJ, Hohnyard DP, Puri MC, Mbamalu G, Harpal K, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995; 377: 695–701.
   PubMed Web of Science ®Google Scholar
• Karim FD, Rubin GM. Ectopic expression of activated Rasl induces hyperplastic growth and increased cell death in Drosophila imaginal tissues. Development 1998; 125: 1–9.
   PubMedGoogle Scholar
• Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, et al. Cellular commitment to oncogene- induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829–39.
   PubMed Web of Science ®Google Scholar
• Ma P, Magut M, Chen X, Chen CY. P53 is necessary for the apoptotic response mediated by a transient increase of Ras activity. Mol Cell Biol 2002; 22: 2928–38.
   PubMedGoogle Scholar
• Palmer° I, Pantoja C, Serrano M. p19ARF links the tumour suppressor 1353 to Ras. Nature 1998; 395: 125–6.
   PubMedGoogle Scholar
• Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000; 103: 321–30.
   PubMed Web of Science ®Google Scholar
• Lin AW, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci USA 1999; 98: 5025–30.
   Google Scholar
• Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997; 278: 1812–5.
   PubMed Web of Science ®Google Scholar
• Feig LA, Buchsbaum RJ. Cell signaling: life or death decisions of ras proteins. Curr Biol 2002; 12: R259–61.
   PubMedGoogle Scholar
• Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000; 275: 35669–72.
   PubMed Web of Science ®Google Scholar
• Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, Broggini M, et al. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 1999; 59: 4662–7.
   Google Scholar
• Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315–9.
   PubMed Web of Science ®Google Scholar
• Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691–9.
   PubMed Web of Science ®Google Scholar
• Vavvas D, Li X, Avruch J, Zhang XF. Identification of Norel as a potential Ras effector. J Biol Chem 1998; 273: 5439–42.
   PubMed Web of Science ®Google Scholar
• Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang X, et al. Identification of a novel ras-regulated proapoptotic pathway. Curr Biol 2002; 12: 253–65.
   PubMed Web of Science ®Google Scholar
• Creasy CL, Chernoff J. Cloning and characterization of a human protein kinase with homology to Ste20. J Biol Chem 1995; 270: 21695–700.
   PubMed Web of Science ®Google Scholar
• Lee KK, Murakawa M, Nishida E, Tsubuki S, Kawashima S, Sakamaki K, et al. Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis. Oncogene 1998; 16: 3029–37.
   PubMedGoogle Scholar
• Graves JD, Gotoh Y, Draves KE, Ambrose D, Han DK, Wright M, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mstl. EMBO J 1998; 17: 2224–34.
   PubMed Web of Science ®Google Scholar
• Coultas L, Strasser A. The molecular control of DNA damage-induced cell death. Apoptosis 2000; 5: 491–507.
   PubMed Web of Science ®Google Scholar
• Rich T, Allen R, Wyllie A. Defying death after DNA damage. Nature 2000; 407: 777–83.
   PubMed Web of Science ®Google Scholar
• Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53- dependent and independent pathways. Nature 1993; 362: 849–52.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847–9.
   PubMed Web of Science ®Google Scholar
• Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 1993; 82: 1092–6.
   PubMed Web of Science ®Google Scholar
• Merritt A, Potten C, Kemp C, Hickman J, Balmain A, Lane D, et al. Role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54: 614–7.
   PubMed Web of Science ®Google Scholar
• Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, et al. Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene 1997; 14: 523–31.
   PubMedGoogle Scholar
• Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807–10.
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr., Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343–9.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Achilles' heel of cancer? Nature 2001; 412: 865–6.
   PubMedGoogle Scholar
• Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin Oncol 2001; 28: 105–14.
   PubMedGoogle Scholar
• Verma IM, Somia N. Gene therapy - promises, problems and prospects. Nature 1997; 389: 239–42.
   PubMed Web of Science ®Google Scholar
• Hupp TR, Lane DP, Ball K. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000; 352: 1–17.
   PubMed Web of Science ®Google Scholar
• Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997; 3: 632–8.
   PubMed Web of Science ®Google Scholar
• Selivanova G, Ryabchenko L, jansson E, Iotsova V, Wiman KG. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999; 19: 3395–402.
   Google Scholar
• Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low- molecular-weight com-pound. Nat Med 2002; 8: 282–8.
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, Korsmeyer SJ. Bc1-2 heterodi- merizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609–19.
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–9.
   PubMed Web of Science ®Google Scholar
• Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471–8.
   Google Scholar
• Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999; 59: 2121–6.
   Google Scholar
• Honda T, Gjertsen BT, Spurgers KB, Briones F, Lee SJ, Hobbs ML, et al. Restoration of bax in prostate cancer suppresses tumor growth and augments therapeutic cell death induction. Anticancer Res 2001; 21: 3141–6.
   PubMedGoogle Scholar
• Soengas SM, Capodieci P, Polsky D, Mora J, EsteIler M, Opitz-Araya X, et at. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207–11.
   PubMed Web of Science ®Google Scholar
• Teitz T, Wei T, Valentine M, Vanin E, Grenet J, Valentine V, et al. Caspase 8 is deleted or silenced preferen-tially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529–35.
   PubMed Web of Science ®Google Scholar
• Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in neuroblasto-ma cells correlates with a loss of caspase-8 expression. Cancer Res 2001; 61: 1314–9.
   PubMed Web of Science ®Google Scholar
• Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810–6.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Stevenson JP, O'Dwyer PJ. Antisense thera-peutics: lessons from early clinical trials. Curr Opin Oncol 2001; 13: 499–505.
   PubMedGoogle Scholar
• Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. Bc1-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 2000; 114: 725–30.
   PubMed Web of Science ®Google Scholar
• Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, et at. bc1-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998; 4: 232–4.
   PubMed Web of Science ®Google Scholar
• Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, et at. Phase I clinical and pharmacokinetic study of bc1-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J CI in Oncol 2000; 18: 1812–23.
   PubMed Web of Science ®Google Scholar
• Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60: 2805–9.
   PubMed Web of Science ®Google Scholar
• Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; 2: 235–41.
   PubMed Web of Science ®Google Scholar
• Wang J-1-, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bc1-2 protein and induces apoptosis of tumor cells. Proc Nat! Acad Sci USA 2000; 97: 7124–9.
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153–64.
   PubMed Web of Science ®Google Scholar
• old U. Tumor necrosis factor (TNF). Science 1985; 230: 630–2.
   PubMed Web of Science ®Google Scholar
• Liu Z-G, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cell 1996; 87: 565–76.
   PubMed Web of Science ®Google Scholar
• Van Antwerp DJ, Martin SJ, Kaki T, Green DR, Verma Suppression of TNF-a-induced apoptosis by NF-kB. Science 1996; 274: 787–9.
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 1996; 274: 784–7.
   PubMed Web of Science ®Google Scholar
• Beg AA, Baltimore D. An essential role for NF-kB in preventing TNF-a-induced cell death. Science 1996; 274: 782–4.
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Cusack JC, Liu R, Baldwin AS. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kB. Nat Med 1999; 5: 412–7.
   Google Scholar
• Loelcsley RI\4, Killeen N, Lenard() MI The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487–501.
   PubMedGoogle Scholar
• Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Biol 1998; 10: 559–63.
   Google Scholar
• Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–62.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–63.
   Google Scholar
• French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999; 5: 146–7.
   Google Scholar
• Walczak H, &Inchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bc1-2- or Bc1-xL-overexpres-sing chemotherapy-resistant tumor cells. Cancer Res 2000; 60: 3051–7.
   PubMed Web of Science ®Google Scholar
• Da Costa LT, Jen J, He TC, Chan TA, Kinzler KW, Vogelstein B. converting cancer genes into killer genes. Proc Natl Acad Sci USA 1996; 93: 4192–6.
   PubMedGoogle Scholar
• Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–6.
   PubMed Web of Science ®Google Scholar
• Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001; 412: 914–7.
   PubMed Web of Science ®Google Scholar
• Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et at. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400: 468–72.
   PubMed Web of Science ®Google Scholar
• Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001; 15: 3249–62.
   PubMed Web of Science ®Google Scholar
• Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57–60.
   PubMed Web of Science ®Google Scholar
• Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, DOLT A, Johnston JF, et at. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001; 92: 1265–71.
   PubMed Web of Science ®Google Scholar
• Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, et al. A phase I trial of the farnesyl transferase inhibitor 5CH66336: evidence for biological and clinical activity. Cancer Res 2000; 60: 1871–7.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et at. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–6.
   PubMed Web of Science ®Google Scholar
• Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148. Cell Death Differ 1998; 5: 710–5.
   PubMed Web of Science ®Google Scholar
• Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, et al. CGP57148B (STI-571) induces differ- entiation and apoptosis and sensitizes Bcr-Abl-positive hu-man leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96: 2246–53.
   PubMed Web of Science ®Google Scholar